齐拉西酮治疗老年期精神分裂症的疗效与安全性  

Efficacy and safety of Ziprasidone in the treatment of senile schizophrenia

作　　者：韩嫣[1] 

机构地区：[1]新乡医学院第二附属医院,河南新乡453002

出　　处：《中国民康医学》2011年第14期1712-1712,1775,共2页Medical Journal of Chinese People’s Health

摘　　要：目的:观察齐拉西酮治疗老年期精神分裂症的疗效与安全性。方法:将82例老年期精神分裂症分为齐拉西酮组和利培酮组各41例,分别用齐拉西酮及利培酮治疗。于治疗前及治疗第2、4、6周末,采用PANSS量表评定疗效,采用TESS评定不良反应。结果:治疗6周末,齐拉西酮组PANSS总分、阳性症状分、阴性症状分、一般精神病理症状分与治疗前相比差异有显著意义,有效率95%;利培酮组有效率92.5%,齐拉西酮组总体疗效与利培酮组相当。两组不良反应均轻微。结论:齐拉西酮治疗精神分裂症与利培酮疗效相当,不良反应少,安全性好。Objective ：To explore the difference of curative efficacy and safety of Ziprasidone and Risperidone in the treatment of senile schizophrenia. Methods：82 patients with senile schizophrenia were divided into Ziprasidone group and Risperidone group for 6 weeks. The curative effects and adverse reactions were assessed with the PANSS and TESS before treatment and at the end of 1,2,4,6 week of treatment respectively. Results： Compared with before treatment, the Ziprasidone group of PANSS total score, positive symptoms, negative symptoms of points, the general psychopathology symptoms was significant difference at the end of 6 weeks, the effectual rates of the two groups were 95 % （ ziprasidone group） and 92.5 % （ risperidone group）, there were no significant difference between the two groups in the overall efficacy. Conclusion：Ziprasidone has significant curative efficacy, milder adverse reactions and higher safety.

关 键 词：齐拉西酮 利培酮 老年期精神分裂症 

分 类 号：R749.3[医药卫生—神经病学与精神病学]